Sandbox Reserved 1176

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 45: Line 45:
== Biological Relevance ==
== Biological Relevance ==
===Neurotensin===
===Neurotensin===
-
<scene name='72/721548/Neurotensin/3'>Neurotensin</scene> is a 13 amino acid '''[https://en.wikipedia.org/wiki/Peptide peptide]''' that is found in both '''[https://en.wikipedia.org/wiki/Nervous_tissue nervous]''' and peripheral tissues. It functions as a '''[https://en.wikipedia.org/wiki/Hormone hormone]''' and a '''[https://en.wikipedia.org/wiki/Neurotransmitter neurotransmitter]''' by activating the G-protein coupled receptor NTSR1<ref name= "SPGP"/>
+
<scene name='72/721548/Neurotensin/3'>Neurotensin</scene> is a 13 amino acid '''[https://en.wikipedia.org/wiki/Peptide peptide]''' that is found in both '''[https://en.wikipedia.org/wiki/Nervous_tissue nervous]''' and peripheral tissues <ref name= "SPGP"/>. It functions as a '''[https://en.wikipedia.org/wiki/Hormone hormone]''' and a '''[https://en.wikipedia.org/wiki/Neurotransmitter neurotransmitter]''' by activating the G-protein coupled receptor, NTSR1<ref name= "SPGP"/>.
===Leptin Research===
===Leptin Research===

Revision as of 02:48, 22 April 2016

An interactive view of the class A GPCR, NTSR1 (blue). This protein gets its activity from binding to the 13 amino acid ligand, NTS (red).

Drag the structure with the mouse to rotate

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 Krumm BE, White JF, Shah P, Grisshammer R. Structural prerequisites for G-protein activation by the neurotensin receptor. Nat Commun. 2015 Jul 24;6:7895. doi: 10.1038/ncomms8895. PMID:26205105 doi:http://dx.doi.org/10.1038/ncomms8895
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 White JF, Noinaj N, Shibata Y, Love J, Kloss B, Xu F, Gvozdenovic-Jeremic J, Shah P, Shiloach J, Tate CG, Grisshammer R. Structure of the agonist-bound neurotensin receptor. Nature. 2012 Oct 25;490(7421):508-13. doi: 10.1038/nature11558. Epub 2012 Oct 10. PMID:23051748 doi:http://dx.doi.org/10.1038/nature11558
  3. 3.0 3.1 3.2 3.3 Liang Y, Boules M, Li Z, Williams K, Miura T, Oliveros A, Richelson E. Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice. Neuropharmacology. 2010 Jun;58(8):1199-205. doi:, 10.1016/j.neuropharm.2010.02.015. Epub 2010 Mar 6. PMID:20211191 doi:http://dx.doi.org/10.1016/j.neuropharm.2010.02.015
  4. 4.0 4.1 4.2 Carraway RE, Plona AM. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides. 2006 Oct;27(10):2445-60. Epub 2006 Aug 2. PMID:16887236 doi:http://dx.doi.org/10.1016/j.peptides.2006.04.030
  5. 5.0 5.1 5.2 Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov. 2012 May 18;11(6):462-78. doi: 10.1038/nrd3702. PMID:22596253 doi:http://dx.doi.org/10.1038/nrd3702
Personal tools